SCHEMBL856159

SCHEMBL856159

COc1c(Cl)cc2c(N3CCOc4ccc(-c5ccc6nc(C)[nH]c6c5)cc4C3)ncnc2c1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 8/20 0.45
LMNA P02545 7/20 0.35
CYP1A2 P05177 7/20 0.35
CYP2C19 P33261 7/20 0.35
ALDH1A1 P00352 6/20 0.35
MAPK1 P28482 6/20 0.35
HIF1A Q16665 6/20 0.35
CYP3A4 P08684 6/20 0.35
CYP2D6 P10635 6/20 0.35
CLK4 Q9HAZ1 5/20 0.35
USP2 O75604 4/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
TSHR P16473 3/20 0.35
TERT O14746 1/20 0.35
GAK O14976 1/20 0.34
KDM4E B2RXH2 3/20 0.33
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HTT P42858 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL857459 0.92 PIK3CA (0.45) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL15604011 0.90 PIK3CA (0.48) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL856799 0.89 PIK3CA (0.45) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL856471 0.88 PIK3CA (0.46) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL857836 0.88 PIK3CA (0.45) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL856295 0.88 PIK3CA (0.47) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL858160 0.88 PIK3CA (0.45) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL7860271 0.87 PIK3CA (0.47) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL856472 0.86 PIK3CA (0.47) PIK3CALMNACYP1A2CYP2C19ALDH1A1
SCHEMBL857949 0.86 PIK3CA (0.46) PIK3CALMNACYP1A2CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US claimed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PIK3CA 3/4885LMNA 2593/4885CYP1A2 997/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PIK3CA 3/4885LMNA 2157/4885CYP1A2 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.